• Explore /
  • Poster
  • / Phase 2 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder.

Phase 2 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder.

Abstract Poster

Authors

null

Guarionex Joel DeCastro

Columbia University Irving Medical Center, New York, NY

Guarionex Joel DeCastro , Christopher B. Anderson , Cory Abate-Shen , Jillian Gray , Justin Ingram , Mark N. Stein , James M. McKiernan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT02202772

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4616)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4616

Abstract #

TPS4616

Poster Bd #

100b

Abstract Disclosures

Similar Posters

First Author: Guarionex Joel DeCastro

First Author: Sunil H. Patel

First Author: Zongren Wang

First Author: Hailiang Zhang